Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XLAB vs WORX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

WORX Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–2 Matrix Metrics)

WORX Overall Winner 6-Pillar Tally: XLAB 0 – 5 WORX (1 Tie) Matrix Metrics: XLAB 2 – 6 WORX

As of Nov 16, 2026, SC WORX Corp (WORX) is the stronger overall head-to-head candidate over XLAB (XLAB) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XLAB carries a Unified Composite Score of 49.8/100 (HOLD) at $1.96 (N/M Forward P/E, N/A operating margin), whereas WORX carries 34.1/100 (SELL) at $1.15 (N/M Forward P/E, -20.1% operating margin).

  • Composite vs. Pillar Nuance: While XLAB currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. WORX 34.1/100 SELL), WORX captures the overall institutional head-to-head verdict (6–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-20.1% vs. N/A operating margin) and revenue trajectory (+3.4% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XLAB vs WORX
XLAB US Equity
XLAB
Institutional Equity
$1.96
-8.41% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -2.58β · 532% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
WORX NASDAQ Head-to-Head Winner
SC WORX Corp
Services-Computer Processing & Data Preparation
$1.15
-6.5% 1D
Market Cap $1.7M
TTM Revenue $2.9M
Forward P/E N/M
Beta / 30D Vol 23.01β · 208% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 15.0 Fund 31.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.8% over 20 days), RSI 71
RSI-14: 71.4 · SMA20: $0.24 · SMA50: $0.24

6-Pillar Scorecard Institutional Category Breakdown (XLAB 0 – 5 WORX)

Columns: Metric · XLAB · WORX
1. Valuation Multiples WORX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.6x
2. Growth & Scale WORX
Revenue Growth (YoY) N/A +3.4%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $2.9M
Market Cap N/A $1.7M
3. Profitability & Quality WORX
Gross Margin N/A 44.7%
Operating Margin N/A -20.1%
Net Profit Margin N/A -80.5%
Return on Equity (ROE) N/A -38.1%
4. Balance Sheet & Cash Flow WORX
Cash Generation (TTM) N/A -$914,262
Cash Flow Margin N/A -31.2%
Net Cash / Leverage N/A ROE $77.66 Book/Sh · -38.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat WORX
OpEx & R&D Intensity N/A 64.8% of Rev ($1.9M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XLAB (2) vs WORX (6)
Institutional Metric XLAB WORX Criterion Row Edge
Market Capitalization
Scale
N/A $1.7M Larger Scale WORX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +3.4% Higher Growth WORX
Operating Margin (TTM)
Profitability
N/A -20.1% Higher Margin WORX
Net Profit Margin
Profitability
N/A -80.5% Higher Margin WORX
Return on Equity (ROE)
Capital Efficiency
N/A -38.1% Higher ROE WORX
52-Week Range Position
Momentum
18% ($1–$7) 17% ($0–$6) Stronger Trend XLAB
Beta / 30D Volatility
Risk Regime
-2.58β · 532% Vol 23.01β · 208% Vol Lower Realized Risk WORX
Unified Institutional Score
Composite Signal
49.8 / 100 (HOLD) 34.1 / 100 (SELL) Higher Composite XLAB
Trailing 12M Revenue (USD)
Operating Scale
N/A $2.9M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 44.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$914,262 ($77.66 Book/Sh · -38.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XLAB +0.07 pp
XLAB: -16.6% · WORX: -16.67%
3M Horizon XLAB +172.16 pp
XLAB: +92.16% · WORX: -80.0%
6M Horizon XLAB +172.16 pp
XLAB: +92.16% · WORX: -80.0%
1Y Horizon XLAB +172.16 pp
XLAB: +92.16% · WORX: -80.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XLAB vs WORX. Trailing 12-month operating profitability (XLAB N/A vs WORX -20.1%) and valuation multiples (XLAB N/M vs WORX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

XLAB ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
WORX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.9M
Gross Margin44.7%
Op. Margin-20.1%
ROE / Fwd P/E-38.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
WORX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WORX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XLAB Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
WORX Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $1.7M market capitalization and -20.1% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($1.9M)
90D Engineering Disclosures 0 Published

Investor FAQ XLAB vs WORX Key Questions & Quantitative Answers

As of Nov 16, 2026, SC WORX Corp (WORX) is the stronger overall head-to-head candidate over XLAB (XLAB) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XLAB carries a Unified Composite Score of 49.8/100 (HOLD) at $1.96 (N/M Forward P/E, N/A operating margin), whereas WORX carries 34.1/100 (SELL) at $1.15 (N/M Forward P/E, -20.1% operating margin). Composite vs. Pillar Nuance: While XLAB currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. WORX 34.1/100 SELL), WORX captures the overall institutional head-to-head verdict (6–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-20.1% vs. N/A operating margin) and revenue trajectory (+3.4% vs. N/A YoY).

WORX leads the Growth & Scale pillar: XLAB posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with WORX at +3.4% YoY revenue growth and +0.0% YoY earnings growth on $2.9M TTM revenue (44.7% gross margin, -20.1% operating margin). On trailing 12-month operating scale, XLAB generates N/A in USD-normalized revenue versus $2.9M for WORX. In operating R&D and SG&A reinvestment, XLAB deploys N/A (0 90-day corporate R&D disclosures) versus 64.8% of Rev ($1.9M) (0 disclosures) for WORX.

WORX screens cheaper on headline valuation multiples. XLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas WORX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-31.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XLAB (N/A ROE) versus WORX (-38.1% ROE) capital efficiency.

In options market volatility and institutional positioning, XLAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-2.58β · 532% Vol realized risk). By comparison, WORX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (23.01β · 208% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.